

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TEAMWAY

International Group Holdings Limited

TEAMWAY INTERNATIONAL GROUP HOLDINGS LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 01239)

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND THE BOARD COMMITTEES

The Board announces that with effect from 30 November 2025:

1. Dr. Tsang Hing Bun resigned as an independent non-executive Director as he would like to devote more time to his other business commitment and ceased to be the chairman of the Audit Committee and the Remuneration Committee, and a member of the Nomination Committee; and
2. Mr. Shiu Shu Ming has been appointed as an independent non-executive Director and the chairman of the Audit Committee and the Remuneration Committee, and a member of the Nomination Committee.

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Teamway International Group Holdings Limited (the “**Company**”, together with its subsidiaries, collectively, the “**Group**”) announces that:

1. Dr. Tsang Hing Bun (“**Dr. Tsang**”) resigned as an independent non-executive Director as he would like to devote more time to his other business commitment; and
2. Mr. Shiu Shu Ming (“**Mr. Shiu**”) has been appointed as an independent non-executive Director,

all with effect from 30 November 2025.

Dr. Tsang has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation as independent non-executive Director that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The biographical information of Mr. Shiu is as follows:

Mr. SHIU Shu Ming, aged 56, graduated from City University of Hong Kong with a bachelor’s degree in Accounting. Mr. Shiu completed his professional training at PricewaterhouseCoopers and is a member of the Hong Kong Institute of Certified Public Accountants. He has over 25 years of experience in corporate finance, specializing in mergers and acquisitions, investments, initial public offerings, and various fundraising activities. His transaction portfolio covers private enterprises, PRC state-owned enterprises, as well as listed companies in Hong Kong, Mainland China, Malaysia, Singapore, and Indonesia. In addition to corporate finance, Mr. Shiu has been actively involved in investment and operations in the healthcare and wellness sectors.

Mr. Shiu has been appointed as an independent non-executive director of Tianjin Construction Development Group Company Limited (stock code: 2515, a company listed on the Main Board of the Stock Exchange) since April 2024. Mr. Shiu served as an independent non-executive director of Beijing Biostar Pharmaceuticals Co., Ltd. (stock code: 2563, a company listed on the Main Board of the Stock Exchange) since May 2025. Mr. Shiu was appointed as a non-executive director of Orient Securities International Holdings Limited (stock code: 8001, a company listed on the GEM of the Stock Exchange but was delisted on 13 November 2025) in June 2022 and was re-designated as an executive director in July 2022. Mr. Shiu was appointed as a non-executive director of Oriental Payment Group Holdings Limited (stock code: 8613, a company listed on the GEM of the Stock Exchange) from December 2021 to July 2025. Mr. Shiu also served as an independent non-executive director of Tianyun International Holdings Limited (stock code: 6836, a company listed on the Main Board of the Stock Exchange but was delisted on 7 January 2025) from April 2022 to January 2025. In addition, Mr. Shiu held position as an executive director and a non-executive director at Town Health International Medical Group Limited (stock code: 3886, a company listed on the Main Board of the Stock Exchange) and Allegro Culture Limited (stock code: 0550, a company listed on the Main Board of the Stock Exchange) from November 2022 to June 2023 and from January 2023 to September 2023, respectively.

Save as disclosed above, Mr. Shiu (i) has not held any directorships in any public companies listed in Hong Kong or other major exchanges in the past three years; (ii) did not have or was not deemed to have any interest or short position (within the meaning of Part XV of the SFO) in any shares, underlying shares or debentures of the Company or its associated corporations; (iii) did not have any relationship with any Director, senior management, substantial shareholder or controlling shareholder of the Company; and (iv) did not hold other positions within the Group. There is no other information in relation to the appointment of Mr. Shiu that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of Listing Rules and there is no other matter in relation to the appointment of Mr. Shiu that needs to be brought to the attention of the shareholders of the Company.

As at the date of this announcement, Mr. Shiu has entered into a letter of appointment with the Company in relation to his appointment as an independent non-executive Director. The letter of appointment is determinable by either party serving on the other not less than three months' written notice. He is subject to retirement at the next following annual general meeting of the Company, at which he will be eligible for re-election, and thereafter subject to retirement by rotation at least once every three years in accordance with the memorandum and articles of association of the Company. Pursuant to the terms of the letter of appointment entered into between the Company and Mr. Shiu, he will be entitled to an annual remuneration of HK\$192,000 which is determined by the Board by reference to his experience, duties and responsibilities with the Company, the Company's remuneration policy as well as prevailing market rates and will be subject to review by the remuneration committee of the Company (the "**Remuneration Committee**") from time to time.

The Board would like to extend its appreciation to Dr. Tsang for his valuable contribution during his tenure of office in the Company, and also welcome Mr. Shiu for joining the Board.

CHANGE OF COMPOSITION OF THE BOARD COMMITTEES

The Board also announces the following change of composition of the Board committees, all with effect from 30 November 2025:

1. Following the resignation of Dr. Tsang as an independent non-executive Director, he ceased to be the chairman of the audit committee of the Company (the "**Audit Committee**") and the Remuneration Committee, and a member of the nomination committee of the Company (the "**Nomination Committee**"); and

2. Mr. Shiu has been appointed as the chairman of the Audit Committee and the Remuneration Committee, and a member of the Nomination Committee.

By order of the Board
Teamway International Group Holdings Limited
Zeng Wenyong
Executive Director

Hong Kong, 28 November 2025

As at the date of this announcement, the executive Director is Mr. Zeng Wenyong; the non-executive Director is Mr. Lee Hung Yuen; and the independent non-executive Directors are Dr. Tsang Hing Bun, Mr. Chow Wai Hung Enzo and Ms. Kwan Wai Ling.

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.